-$0.59 Earnings Per Share Expected for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) This Quarter

Share on StockTwits

Equities research analysts forecast that Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) will report ($0.59) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Momenta Pharmaceuticals’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.81). Momenta Pharmaceuticals posted earnings per share of ($0.07) during the same quarter last year, which would suggest a negative year-over-year growth rate of 742.9%. The business is expected to announce its next earnings report on Friday, February 28th.

According to Zacks, analysts expect that Momenta Pharmaceuticals will report full-year earnings of ($2.58) per share for the current year, with EPS estimates ranging from ($2.88) to ($2.10). For the next year, analysts expect that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.51) to ($1.74). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Momenta Pharmaceuticals.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.09). The firm had revenue of $6.40 million for the quarter, compared to the consensus estimate of $5.24 million. Momenta Pharmaceuticals had a negative return on equity of 59.82% and a negative net margin of 361.66%. The business’s revenue was down 57.0% on a year-over-year basis. During the same period last year, the company posted ($0.65) EPS.

A number of equities research analysts have weighed in on the company. Piper Jaffray Companies set a $35.00 target price on Momenta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 17th. SunTrust Banks started coverage on Momenta Pharmaceuticals in a report on Tuesday, November 12th. They set a “buy” rating and a $29.00 price target for the company. ValuEngine raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 1st. HC Wainwright assumed coverage on Momenta Pharmaceuticals in a research report on Wednesday, September 25th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Wells Fargo & Co assumed coverage on Momenta Pharmaceuticals in a research note on Wednesday, November 6th. They issued an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Momenta Pharmaceuticals presently has an average rating of “Buy” and an average price target of $23.45.

In related news, CEO Craig A. Wheeler sold 2,601 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.16, for a total transaction of $42,032.16. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Anthony M. Manning sold 6,365 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $13.83, for a total value of $88,027.95. Following the sale, the insider now directly owns 20,603 shares in the company, valued at approximately $284,939.49. The disclosure for this sale can be found here. In the last three months, insiders sold 177,262 shares of company stock valued at $2,862,158. 3.40% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Momenta Pharmaceuticals by 2.9% during the second quarter. BlackRock Inc. now owns 15,606,505 shares of the biotechnology company’s stock worth $194,302,000 after purchasing an additional 438,679 shares during the last quarter. Vanguard Group Inc. boosted its position in Momenta Pharmaceuticals by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 10,436,152 shares of the biotechnology company’s stock worth $129,931,000 after buying an additional 129,762 shares during the period. Perceptive Advisors LLC boosted its position in Momenta Pharmaceuticals by 1.0% during the 2nd quarter. Perceptive Advisors LLC now owns 2,905,000 shares of the biotechnology company’s stock worth $36,167,000 after buying an additional 30,000 shares during the period. Point72 Asset Management L.P. grew its holdings in Momenta Pharmaceuticals by 1,147.0% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,581,229 shares of the biotechnology company’s stock worth $33,453,000 after acquiring an additional 2,374,229 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Momenta Pharmaceuticals by 0.9% during the 2nd quarter. Northern Trust Corp now owns 1,275,473 shares of the biotechnology company’s stock worth $15,879,000 after acquiring an additional 11,012 shares during the last quarter. Hedge funds and other institutional investors own 97.04% of the company’s stock.

MNTA traded up $1.17 during trading on Friday, hitting $18.02. 1,063,160 shares of the stock traded hands, compared to its average volume of 539,580. Momenta Pharmaceuticals has a twelve month low of $9.51 and a twelve month high of $18.06. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -8.88 and a beta of 2.07. The business has a 50 day moving average price of $15.76 and a 200 day moving average price of $13.11.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Read More: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Momenta Pharmaceuticals (MNTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hartford Financial Services Group Inc  Shares Sold by Benin Management CORP
Hartford Financial Services Group Inc Shares Sold by Benin Management CORP
SYSCO Co.  Position Reduced by Benin Management CORP
SYSCO Co. Position Reduced by Benin Management CORP
Benin Management CORP Purchases 1,000 Shares of Merck & Co., Inc.
Benin Management CORP Purchases 1,000 Shares of Merck & Co., Inc.
11,677 Shares in Truist Financial Corporation  Acquired by Benin Management CORP
11,677 Shares in Truist Financial Corporation Acquired by Benin Management CORP
Benin Management CORP Decreases Stock Holdings in Paychex, Inc.
Benin Management CORP Decreases Stock Holdings in Paychex, Inc.
Benin Management CORP Decreases Stock Position in Halliburton
Benin Management CORP Decreases Stock Position in Halliburton


© 2006-2020 Ticker Report